文献速递类风湿关节炎

IL-6抑制剂与JAK抑制剂作为贫血合并类风湿关节炎患者的有利治疗选择:ANSWER队列研究

IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

基于日本ANSWER多中心观察性注册队列2093例类风湿关节炎患者,按基线血红蛋白三分位分组,比较不同作用机制b/ts-DMARDs治疗后的血红蛋白变化、药物留存率和疾病活动度。IL-6R抑制剂在全部三组均升高血红蛋白,JAK抑制剂在贫血组升高血红蛋白。贫血患者中JAK抑制剂总体调整3年药物留存率最高(78.6%),其次为IL-6R抑制剂(67.9%)、CTLA4-Ig(61.8%)和TNF抑制剂(50.8%)。

要点

  • IL-6R抑制剂在贫血组12个月血红蛋白平均变化为+1.5 g/dl,中间组+0.7 g/dl,非贫血组+0.1 g/dl。
  • JAK抑制剂在贫血组12个月血红蛋白平均变化为+0.6 g/dl,中间组0 g/dl,非贫血组-0.3 g/dl。
  • 贫血患者中总体调整3年药物留存率JAK抑制剂78.6%,IL-6R抑制剂67.9%,CTLA4-Ig 61.8%,TNF抑制剂50.8%。

核心结论

  • IL-6R抑制剂和JAK抑制剂可在真实世界环境中有效治疗贫血合并类风湿关节炎患者。

研究设计与样本

  • 基于日本类风湿关节炎多中心观察性注册队列(ANSWER队列)的研究。
  • 共纳入2093例类风湿关节炎患者,按基线血红蛋白水平三分位分为三组(Hblow贫血组、Hbint中间组、Hbhigh非贫血组)。
  • 比较不同作用机制b/ts-DMARDs(TNF抑制剂、CTLA-4-Ig、IL-6受体抑制剂、Janus激酶抑制剂)治疗后的血红蛋白变化、药物留存率和疾病活动度。

主要发现

  • IL-6R抑制剂在全部三组均升高血红蛋白水平,12个月时Hblow组平均变化+1.5 g/dl,Hbint组+0.7 g/dl,Hbhigh组+0.1 g/dl。
  • JAK抑制剂在贫血合并类风湿关节炎患者中升高血红蛋白水平,在非贫血患者中维持或降低血红蛋白水平,12个月时Hblow组平均变化+0.6 g/dl,Hbint组0 g/dl,Hbhigh组-0.3 g/dl。
  • 贫血合并类风湿关节炎患者中,总体调整3年药物留存率由高到低依次为JAK抑制剂78.6%、IL-6R抑制剂67.9%、CTLA4-Ig 61.8%、TNF抑制剂50.8%。
  • 不同b/ts-DMARDs治疗之间12个月疾病活动度变化无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anaemia, a common comorbidity of RA, is related to high disease activity and poor prognosis. It is unknown which biologic/targeted synthetic (b/ts)-DMARDs are optimal for patients with anaemia and RA in regulating anaemia and controlling disease activity. METHODS: We investigated the change in haemoglobin (Hb) levels, drug retention rates and disease activities after the administration of b/ts-DMARDs with different modes of action [TNF inhibitors (TNFis), immunoglobulin fused with cytotoxic T-lymphocyte antigen (CTLA-4-Ig), IL-6 receptor inhibitors (IL-6Ris) and Janus kinase inhibitors (JAKis)] in patients with RA stratified by baseline Hb levels using the multicentre observational registry for patients with RA in Japan (ANSWER cohort). RESULTS: A total of 2093 patients with RA were classified into three groups based on tertiles of the baseline Hb levels (Hblow, anaemic; Hbint, intermediate; Hbhigh, non-anaemic). IL-6Ri increased Hb levels in all groups (the mean change at 12 months in Hblow was +1.5 g/dl, Hbint +0.7 g/dl and Hbhigh +0.1 g/dl). JAKis increased the Hb level in patients with anaemia and RA and retained or decreased the Hb level in non-anaemic patients (the mean change at 12 months in Hblow was +0.6 g/dl, Hbint 0 g/dl and Hbhigh -0.3 g/dl). In patients with anaemia and RA, overall adjusted 3-year drug retention rates were higher in JAKi followed by IL-6Ri, CTLA4-Ig and TNFi (78.6%, 67.9%, 61.8% and 50.8%, respectively). Change of disease activity at 12 months was not different among different b/ts-DMARDs treatments. CONCLUSION: IL-6Ri and JAKi can effectively treat patients with anaemia and RA in a real-world setting.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Nakayama Y, Watanabe R, Yamamoto W, et al. IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study. Rheumatology (Oxford). 2024. PMID: 37354495. doi:10.1093/rheumatology/kead299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。